Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6P9OU
|
|||
| Drug Name |
ONC206
|
|||
| Synonyms |
UNII-OW6LM47PNK; OW6LM47PNK; 1638178-87-6; 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; SCHEMBL20464679; ONC-206; NSC783746; s6853; NSC-783746; HY-135147; CS-0109614; 4-((2,4-Difluorophenyl)methyl)-2,4,6,7,8,9-hexahydro-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-E)pyrimidin-5(1H)-one; 7-Benzyl-4-(2,4-difluorobenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Brain and central nervous system tumour [ICD-11: 2A00.11; ICD-10: C69-C72, C71] | Phase 1 | [1] | |
| Company |
Oncoceutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22F2N4O
|
|||
| Canonical SMILES |
C1CN(CC2=C1N3CCN=C3N(C2=O)CC4=C(C=C(C=C4)F)F)CC5=CC=CC=C5
|
|||
| InChI |
1S/C23H22F2N4O/c24-18-7-6-17(20(25)12-18)14-29-22(30)19-15-27(13-16-4-2-1-3-5-16)10-8-21(19)28-11-9-26-23(28)29/h1-7,12H,8-11,13-15H2
|
|||
| InChIKey |
ITMGVSSHWMTJRR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1638178-87-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04541082) Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms. U.S. National Institutes of Health. | |||
| REF 2 | ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro. Front Oncol. 2020 Oct 20;10:577141. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.